TG Therapeutics (TGTX) Set to Announce Quarterly Earnings

TG Therapeutics (NASDAQ:TGTX) is set to release its quarterly earnings report on Monday, November 4, before the market opens. Analysts are anticipating that the company will report earnings of $0.04 per share for the quarter.

Recently, TG Therapeutics published its previous quarterly earnings on August 6, where they reported an earnings per share (EPS) of $0.04, surpassing the consensus expectation of a loss of $0.04 per share by $0.08. The company enjoyed a return on equity of 57.73% and a strong net margin of 27.60%. Revenue for that quarter was recorded at $73.47 million, exceeding the forecast of $65.92 million by a significant margin. In comparison to the same quarter last year, which showed a loss of $0.34 EPS, TG Therapeutics has experienced a remarkable 357.0% increase in revenue year-over-year. Looking forward, analysts predict that TG Therapeutics will achieve a break-even EPS for the current financial year, followed by an expected EPS of $1 for the next year.

TG Therapeutics Stock Performance

On the trading front, TG Therapeutics shares were valued at $26.90 at the market open on Friday, giving the company a market capitalization of $4.16 billion. The stock has a price-to-earnings ratio of 44.10 and a beta of 2.21, indicating higher volatility compared to the market. Financially, TG Therapeutics has a debt-to-equity ratio of 0.58, along with a current ratio of 3.58 and a quick ratio of 2.83. Over the past year, the stock has fluctuated between a low of $9.81 and a high of $26.99, with a 50-day moving average at $23.51 and a 200-day moving average at $20.01.

Analysts' Outlook on TG Therapeutics

Market analysts have been vocal about their perspectives on TG Therapeutics' stock. Recently, The Goldman Sachs Group raised its price target for the stock from $18.00 to $20.00, maintaining a "neutral" rating. Furthermore, TD Cowen recently initiated coverage on TG Therapeutics, giving it a "buy" rating with an aggressive price target of $50.00. HC Wainwright also affirmed their "buy" rating with a price target of $49.00 on September 18. Additionally, B. Riley increased their price objective from $29.00 to $34.00, joining the ranks of those who have recommended a buy. Currently, the consensus rating on the stock is "Moderate Buy" with an average price target of $36.33.

About TG Therapeutics

TG Therapeutics, Inc. is a commercially operating biopharmaceutical firm that works on the acquisition, development, and marketing of innovative treatments for B-cell mediated diseases. The company’s key product is BRIUMVI, an anti-CD20 monoclonal antibody designed to treat adult patients with various forms of relapsing multiple sclerosis.

Earnings, Stocks, Companies